Myosin Therapeutics Closes Second Seed Round To Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies
UF startup Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding round, raising over $3 million to supplement significant investment from the National Institutes of Health.
